Clinical Trial Update: EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing DX-88 (conestat alfa) for reducing angioedema episodes in hereditary angioedema; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• DX-88

Snippet

Sponsor: Shire | Conditions: Hereditary Angioedema (HAE) | Phase 2 | Status: COMPLETED